Effect of Kuibitang on lipopolysaccharide-induced cytokine production in peripheral blood mononuclear cells of chronic fatigue syndrome patients

Journal of Ethnopharmacology

Volumn 90, Issue 2-3, 2004, Pages 253-259

  Shin, Hye Young ^a,b   An, Nyeon Hyoung ^b   Cha, Yun Jin ^c   Shin, Eun Ju ^b   Shin, Tae Yong ^d   Baek, Seung Hwa ^e   Kim, Cheorl Ho ^f   Lyu, Yeung Su ^e   Lee, Eon Jeong ^e   Kim, Hyung Min ^a  

^a Kyung Hee University   (South Korea)

^b Wonkwang University   (South Korea)

^c SinnongC Oriental Clinic   (South Korea)

^d Woosuk University   (South Korea)

^e Wonkwang University   (South Korea)

^f Dongguk University   (South Korea)

Author keywords

Chronic fatigue; Cytokine; Kuibitang; Lipopolysaccharide

Indexed keywords

ANGELICA GIGAS EXTRACT; ASTRAGALUS MEMBRANACEUS EXTRACT; ATRACTYLODES MACROCEPHALA EXTRACT; AUCKLANDIA LAPPA EXTRACT; CYTOKINE; EUPHORIA LONGAN EXTRACT; GAMMA INTERFERON; GINGER EXTRACT; GINSENG EXTRACT; GLYCYRRHIZA URALENSIS EXTRACT; INTERLEUKIN 10; KUIBITANG; LIPOPOLYSACCHARIDE; PLANT EXTRACT; POLYGALA TENUIFOLIA EXTRACT; PORIA COCOS EXTRACT; PRUNELLA VULGARIS EXTRACT; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ZIZIYPHUS SPINOSA EXTRACT; ZIZYPHUS JUJUBA EXTRACT;

ADULT; ANGELICA GIGAS; ARTICLE; ASTRAGALUS MEMBRANACEUS; ATRACTYLODES MACROCEPHALA; AUCKLANDIA LAPPA; CHRONIC FATIGUE SYNDROME; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; EUPHORIA LONGAN; GINGER; GINSENG; GLYCYRRHIZA URALENSIS; HUMAN; HUMAN CELL; JUJUBE; MEDICINAL PLANT; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYGALA TENUIFOLIA; PORIA COCOS; PROTEIN SYNTHESIS INHIBITION; PRUNELLA VULGARIS; ZIZIYPHUS SPINOSA;

EID: 10744227581     PISSN: 03788741     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jep.2003.10.006     Document Type: Article

References (57)

1. Altmann C., Larratt K., Golubjatnikov R., Kirmani N., Rytel M. Immunologic markers in the chronic fatigue syndrome. Clinical Research. 36:1988;845A.
2. Andersson P.O., Olsson A., Wadenvik H. Reduced transforming growth factor-beta1 production by mononuclear cells from patients with active chronic idiopathic thrombocytopenic purpura. British Journal of Hematology. 116:2002;862-867.
3. Aoki T., Miyakoshi H., Usuda Y., Herberman R.B. Low NK syndrome and its relationship to chronic fatigue syndrome. Clinical Immunology and Immunopathology. 3:1993;253-265.
4. Aung H., Toossi Z., McKenna S.M., Gogate P., Sierra J., Sada E., Rich E.A. Expression of transforming growth factor-beta but not tumor necrosis factor-alpha, interferon-gamma, and interleukin-4 in granulomatous lung lesions in tuberculosis. Tubercle and Lung Disease. 80:2000;61-67.
5. Barker, E., Fujimura, S.F., Fadem, M.B., Landay, A.L., Levy, J.A., 1994. Immunologic abnormalities associated with chronic fatigue syndrome. Clinical Infectious Diseases Supplemnt 1, S136-S141.
6. Barral A., Barral-Netto M., Yong E.C., Brownell C.E., Twardzik D.R., Reed S.G. Transforming growth factor beta as a virulence mechanism for Leishmania braziliensis. Proceedings of the National Academy Sciences USA. 90:1993;3442-3446.
7. Bearn J., Wessely S. Neurobiological aspects of the chronic fatigue syndrome. European Journal of Clinical Investigation. 2:1994;79-90.
8. Bennett A.L., Chao C.C., Hu S., Buchwald D., Fagioli L.R., Schur P.H., Peterson P.K., Komaroff A.L. Elevation of bioactive transforming growth factor-beta in serum from patients with chronic fatigue syndrome. Journal of Clinical Immunology. 2:1997;160-166.
9. Border W.A., Ruoslahti E. Transforming growth factor-beta in disease: the dark side of tissue repair. Journal of Clinical Investigation. 90:1992;1-7.
10. Brosnan C.F., Selmaj K., Raine C.S. Hypothesis: a role for tumor necrosis factor in immune-mediated demyelination and its relevance to multiple sclerosis. Journal of Neuroimmunology. 18:1988;87-94.
11. Buchwald D., Komaroff A.L. Review of laboratory findings for patients with chronic fatigue syndrome. Reviews Infectious Disease. 13:1991;S12-S18.
12. Buchwald D., Wener M.H., Pearlman T., Kith P. Markers of inflammation and immune activation in chronic fatigue and chronic fatigue syndrome. Journal of Rheumatology. 2:1997;372-376.
13. Caligiuri M., Murray C., Buchwald D., Levine H., Cheney P., Peterson D., Komaroff A.L., Ritz J. Phenotypic and functional deficiency of natural killer cells in patients with chronic fatigue syndrome. Journal of Immunology. 139:1987;3306-3313.
14. Cannon J.G., Angel J.B., Abad L.W., Vannier E., Mileno M.D., Fagioli L., Wolff S.M., Komaroff A.L. Interleukin-1 beta, interleukin-1 receptor antagonist, and soluble interleukin-1 receptor type II secretion in chronic fatigue syndrome. Journal of Clinical Immunology. 3:1997;253-261.
15. Chao C.C., Janoff E.N., Hu S.X., Thomas K., Gallagher M., Tsang M., Peterson P.K. Altered cytokine release in peripheral blood mononuclear cell cultures from patients with the chronic fatigue syndrome. Cytokine. 3:1991;292-298.
16. Chen Y., Kuchroo V.K., Inobe J., Hafler D.A., Weiner H.L. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science. 265:1994;1237-1240.
17. Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology. 26:1997;112S-121S.
18. Fiorentino D.F., Zlotnik A., Mosmann T.R., Howard M., O'Garra A. IL-10 inhibits cytokine production by activated macrophages. Journal of Immunology. 147:1991;3815-3822.
19. Fukaura H., Kent S.C., Pietrusewicz M.J., Khoury S.J., Weiner H.L., Hafler D.A. Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients. Journal of Clinical Investigation. 98:1996;70-77.
20. Fukuda K., Straus S.E., Hickie I., Sharpe M.C., Dobbins J.G., Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study, International Chronic Fatigue Syndrome Study Group. Annals International Medicine. 121:1994;953-959.
21. Gorelik L., Flavell R.A. Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity. 12:2000;171-181.
22. Gupta S., Aggarwal S., See D., Starr A. Cytokine production by adherent and non-adherent mononuclear cells in chronic fatigue syndrome. Journal of Psychiatric Research. 31:1997;149-156.
23. Gupta, S., 1992. Recent developments in immunological aspects of chronic fatigue syndrome. In: The Clinical and Scientific Basis of Myalgic Encephalomyelitis Chronic Fatigue Syndrome. New York: The Nightingale Research Foundation. pp. 545-550.
24. Gupta S., Vayuvegula B. A comprehensive immunological analysis in chronic fatigue syndrome. Scandinavian Journal of Immunology. 33:1991;319-327.
25. Hassan I.S., Bannister B.A., Akbar A., Weir W., Bofill M. A study of the immunology of the chronic fatigue syndrome: correlation of immunologic parameters to health dysfunction. Clinical Immunology and Immunopathology. 87:1998;60-67.
26. Hirsch C.S., Yoneda T., Averill L., Ellner J.J., Toossi Z. Enhancement of intracellular growth of Mycobacterium tuberculosis in human monocytes by transforming growth factor-beta 1. Journal of Infectious Diseases. 170:1994;1229-1237.
27. Howard M., O'Garra A., Ishida H., Malefyt R., de Vries J. Biological properties of interleukin 10. Journal of Clinical Immunology. 12:1992;239-347.
28. Jone J.F. Serologic and immunologic responses in chronic fatigue syndrome with emphasis on the Epstein-Barr virus. Reviews Infectious Disease. 1:1991;S26-S31.
29. Klimas N.G., Salvato F.R., Morgan R., Fletcher M.A. Immunologic abnormalities in chronic fatigue syndrome. Journal of Clinical Microbiology. 28:1990;1403-1410.
30. Knop J., Stremer R., Nauman C., deMaeyer E., Macher M. Interferon inhibits the suppressor T cell response of delayed hypersensitivity. Nature. 296:1982;757-759.
31. Koyanagi M., Egashira K., Kubo-Inoue M., Usui M., Kitamoto S., Tomita H., Shimokawa H., Takeshita A. Role of transforming growth factor-beta1 in cardiovascular inflammatory changes induced by chronic inhibition of nitric oxide synthesis. Hypertension. 35:2000;86-90.
32. Krakauer, T., Vilcek, J., Oppenheim, J.J., 1999. Proinflammatory cytokines: TNF and IL-1 families, chemokines, TGF-β, and others. In: Paul, W.E. (Ed). Fundamental Immunology. 4th ed. Lippincott-Raven, New York, pp. 775-811.
33. Landay A.L., Jessop C., Lennette E.T., Levy J.A. Chronic fatigue syndrome: clinical condition associated with immune activation. Lancet. 338:1991;707-712.
34. Levy J.A. Viral studies of chronic fatigue syndrome. Clinical Infectious Diseases. 18:1994;S117-S120.
35. Lim D.W., Kim D.H., You D.Y. Effect of Kamiguibitang on immunologic control function. The Journal of Oriental Gynecology. 12:1999;253-280.
36. Lloyed A.R., Wakefield D., Dwyer J., Boughton C. Immunological abnormalities in chronic fatigue syndrome. Medical Journal of Australia. 151:1989;122-124.
37. Lopez A.R., Cook J., Deininger P.L., Derynck R. Dominant negative mutants of transforming growth factor-beta 1 inhibit the secretion of different transforming growth factor-beta isoforms. Molecular and Cellular Biology. 12:1992;1674-1679.
38. Matsuda H., Murakami T., Ikebata A., Yamahara J., Yoshikawa M. Bioactive saponins and glycosides. XIV. Structure elucidation and immunological adjuvant activity of novel protojujubogenin type triterpene bisdesmosides, protojujubosides A, B, and B1, from the seeds of Zizyphus jujuba var. spinosa (Zizyphi Spinosi Semen). Chemical and Pharmaceutical Bulletin. 47:1999;1744-1748.
39. Matsuyama T., Kobayashi N., Yamamoto N. Cytokines and HIV infection: is AIDS a tumor necrosis factor disease? AIDS. 5:1991;1405-1417.
40. Mawle A.C., Nisenbaum R., Dobbins J.G., Gary H.E. Jr., Stewart J.A., Reyes M., Steele L., Schmid D.S., Reeves W.C. Immune responses associated with chronic fatigue syndrome: a case-control study. Journal of Infectious Diseases. 175:1997;136-141.
41. Morte S., Castilla A., Civeira M.P., Serrano M., Prieto J. Gamma-interferon and chronic fatigue syndrome. Lancet. 2:1988;623-624.
42. Moutschen M., Triffaux J.M., Demonty J., Legros J.J., Lefebvre P.J. Pathogenic tracks in fatigue syndromes. Acta Clinica Belgica. 49:1994;274-289.
43. Rasmussen A.K., Nolesen H., Andersen V., Barington T., Bendtzen K., Hansen M.B., Nielsen L., Pedersen B.K., Wiik A. Chronic fatigue syndrome-a controlled cross sectional study. Journal of Rheumatology. 21:1991;1527-1531.
44. Reed S.G. TGF-beta in infections and infectious diseases. Microbes and Infection. 1:1999;1313-1325.
45. Scuderi P., Sterling K.E., Lam K.S., Finley P.R., Ryan K.J., Ray C.G., Petersen E., Slymen D.J., Salmon S.E. Raised serum levels of tumour necrosis factor in parasitic infections. Lancet. 2:1986;1364-1365.
46. Shoham S., Davenne D., Cady A.B., Dinarello C.A., Krueger J.M. Recombinant tumor necrosis factor and interleukin 1 enhance slow-wave sleep. American Journal of Physiology. 253:1987;R142-R149.
47. Straus S.E., Dale J.K., Peter J.B., Dinnarello C.A. Circulating lymphokine levels in the chronic fatigue syndrome. Journal of Infectious Diseases. 160:1989;1085-1086.
48. Strauss S.E., Komaroff A.L., Wedner H.J. Chronic fatigue syndrome. Point and counterpoint. Journal of Infectious Diseases. 170:1994;1-6.
49. Strauss S.E., Fritz S., Dale J.K., Gould B., Strober W. Lympocyte phenotype and function in the chronic fatigue syndrome. Journal of Clinical Immunology. 13:1993;30-40.
50. Swanink C.M.A., Vercoulen J.H.M.M., Bleijenberg G., Fennis J.F.M., Galema J.M.D., van der Meer J.W. Chronic fatigue syndrome: a clinical and laboratory study with a well matched control group. Journal of International Medicine. 237:1993;499-506.
51. Swanink C.M.A., Vercoulen J.H.M.M., Galama J.M.D., Roos M.T., Meyaard L., van der Ven-Jongekrijg J., de Nijs R., Bleijenberg G., Fennis J.F., Miedema F., van der Meer J.W. Lymphocyte subsets, apoptosis, and cytokines in patients with chronic fatigue syndrome. Journal of Infectious Diseases. 173:1996;460-463.
52. Targan S., Stebbing N. In vitro interactions of purified cloned human interferons on NK cells: enhanced activation. Journal of Immunology. 129:1982;934-935.
53. Tirelli U., Marotta G., Improta S., Pinto A. Immunological abnormalities in patients with chronic fatigue syndrome. Scandinavian Journal of Immunology. 40:1994;601-608.
54. van Boxel-Dezaire A.H., Hoff S.C., van Oosten B.W., Verweij C.L., Drager A.M., Ader H.J., van Houwelingen J.C., Barkhof F., Polman C.H., Nagelkerken L. Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis. Annals of Neurology. 45:1999;695-703.
55. Visser J., Blauw B., Hinloopen B., Brommer E., de Kloet E.R., Kluft C., Nagelkerken L. CD4 T lymphocytes from patients with chronic fatigue syndrome have decreased interferon-gamma production and increased sensitivity to dexamethasone. Journal of Infectious Diseases. 2:1998;451-454.
56. Visser J., Graffelman W., Blauw B., Haspels I., Lentjes E., de Kloet E.R., Nagelkerken L. LPS-induced IL-10 production in whole blood cultures from chronic fatigue syndrome patients is increased but supersensitive to inhibition by dexamethasone. Journal of Neuroimmunology. 119:2001;343-349.
57. Ye Y.N., Liu E.S., Li Y., So H.L., Cho C.C., Sheng H.P., Lee S.S., Cho C.H. Protective effect of polysaccharides-enriched fraction from Angelica sinensis on hepatic injury. Life Science. 69:2001;637-646.